" class="no-js "lang="en-US"> Josh Brumm - Medtech Alert
Friday, March 29, 2024
Josh Brumm

Josh Brumm

About Josh Brumm

Biotech Chief Executive Officer. Two approved drugs on the market, raised ~$1.5Bn in capital including taking four companies public. Passionate about leadership, driven by teamwork and committed to winning for patients and creating value for stakeholders.

Related Story

Amphista Therapeutics Appoints New Chairman, Joshua T. Brumm

September 21 2021

Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the […]